BioLineRx Ltd.

BLRX

Healthcare|Biotechnology|IL

$1.71

-0.06 (-3.28%)

DCF Value

$0.18

Tangible Book / Share

$0.00

Cash / Share

$0.07

Clinical Trials (23)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT03246529 A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)	Multiple Myeloma	P3	Active	180	RCT, Double-blind	BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
NCT01363349 Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia	Schizophrenia, Cognitive Effect on Schizophrenic Patients	P2P3	Terminated	269	RCT, Double-blind	CYP-1020, Risperidone
NCT03154827 Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)	Acute Myeloid Leukemia	P1P2	Terminated	1	Open-label	BL-8040, Atezolizumab
NCT02502968 BL-8040 Addition to Consolidation Therapy in AML Patients	Acute Myeloid Leukemia	P2	Unknown	194	RCT, Double-blind	Cytarabine, BL-8040, Placebo (for BL-8040)
NCT00557531 Safety and Feasibility of the Injectable BL-1040 Implant	Cardiovascular Disease	P1P2	Unknown	30	Open-label	—
NCT02462252 Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome	Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome	P2	Completed	11	Open-label	BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine
NCT00374881 A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects	Acute Pain	P1P2	Completed	9	RCT, Double-blind	Morphine, Morphine, Sorbitol+Phenylephrine, Sorbitol+Phenylephrine+Morphine, Sorbitol low concentration+Phenylephrine+Morphine
NCT01506362 Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis	Ulcerative Colitis	P2	Completed	22	Open-label	BL-7040
NCT00480571 Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder	Schizophrenia, Schizoaffective Disorder	P2	Completed	90	Open-label	BL-1020, BL 1020 High Dose
NCT01990885 Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.	Celiac Disease	P1P2	Completed	40	RCT, Double-blind	BL-7010, Placebo
NCT00567710 A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study	Schizophrenia	P2	Completed	360	RCT, Double-blind	BL - 1020, BL - 1020, Placebo, Risperidone
NCT01833845 Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C	Hepatitis C	P1P2	Terminated	4	Open-label	Ribavirin, Hydroxychloroquine
NCT02639559 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies	Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia	P2	Completed	50	Open-label	BL-8040
NCT02826486 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients	Metastatic Pancreatic Adenocarcinoma	P2	Completed	80	Open-label	BL-8040, Pembrolizumab, Chemotherapy
NCT03281369 A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)	Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	P1P2	Terminated	219	RCT, Open-label	5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Atezolizumab, Cobimetinib, Cisplatin, Tiragolumab, 5-Fluorouracil (5-FU)
NCT01838395 Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients	Acute Myeloid Leukemia	P2	Completed	42	Open-label	Ara-C, BL-8040
NCT00722176 Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020	Schizophrenia	P2	Completed	220	RCT, Double-blind	BL-1020, BL-1020 10-30 mg, risperidone
NCT02073019 A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers	Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)	P1	Completed	33	RCT, Double-blind	BL-8040, Placebo
NCT01121380 A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021	Healthy, Volunteers	P1	Terminated	32	RCT, Double-blind	BL-1021, 1021
NCT06547112 A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization	Multiple Myeloma	P1	Completed	20	Open-label	Motixafortide, G-CSF
NCT05293171 Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects	Healthy Subjects	P1	Completed	38	RCT, Double-blind	1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet)
NCT05618301 Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)	Sickle Cell Disease	P1	Completed	10	Open-label	Motixafortide, Natalizumab
NCT00480246 A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer	Healthy	P1	Completed	—	Open-label	BL 1020, Perphenazine